Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.
about
Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates.Antibody drug conjugates.Antibody drug conjugates: lessons from 20 years of clinical experience.Strategies and challenges for the next generation of antibody-drug conjugates.Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality ControlNext-Generation Antibody-Drug Conjugates (ADCs) for Cancer Therapy.Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.Oxetane Grafts Installed Site-Selectively on Native Disulfides to Enhance Protein Stability and Activity In Vivo.Improved Tumor Penetration and Single-Cell Targeting of Antibody Drug Conjugates Increases Anticancer Efficacy and Host Survival.Chemoselective Installation of Amine Bonds on Proteins through Aza-Michael Ligation.Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers.Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer.Drug conjugates—an emerging approach to treat breast cancer.An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.Modular pore-forming immunotoxins with caged cytotoxicity tailored by directed evolution
P2860
Q33721106-EE451BDD-B411-4F10-982E-A9CEECA1CB17Q37606966-95DB523E-803D-4DC8-A5BB-298A98A90A9EQ38738155-00DA7B55-CE80-4394-93E9-2454CEF58F11Q38873862-AE712DAD-BC45-4F6A-8C66-EB92F28854E4Q38979084-A65E9F0B-1BB3-438A-8225-E7BEF79845DBQ39182945-DA77FF77-0EF3-40ED-B0B0-8052763B20ADQ39210427-79280994-1819-419E-B5EF-B7DE3FDDF316Q41280225-32F0C780-AB56-4CF0-8C21-CDAA9A10D648Q41353023-C6506DB7-F9ED-435F-AAAF-B51147F0A301Q43245117-B04D9F6C-15D6-4B2D-A5CB-D8F13478FB62Q46008308-3B024B89-1AC8-4554-8999-D77E23AC034FQ46209550-03B8BA49-9A41-4B96-861C-8571C4781D06Q47119242-C176FF4F-B96B-4A88-BE12-E91CB37B40A2Q47271330-D1FD37E4-D89E-44F9-815D-18D10556A814Q47329996-4B23E7D1-3831-4FFB-9628-E71F85BA245BQ47661007-F674C68C-C4D4-4BF1-91EA-63A899DA9DBAQ47851750-E866891D-9DB1-4F01-9C58-47E2442566D0Q48243258-2ACDEF1A-5441-4C7E-A731-F4B96E396D5FQ52658297-6EA988D5-3D6E-4D98-9407-ACD555C4F6C5Q52676610-2A4352F2-8ADF-4C80-9C6A-D2262A223E21Q55109090-F307BE63-0224-4605-AE30-5A1538225EA6Q55438401-F8AA3B3C-72C9-4CBF-AD15-6F99348B301EQ55439903-1E9365CA-03C2-4B80-BF68-AD6C76D6B25FQ56872060-DC33AB4C-C156-4801-A4B4-D43EBBA9F4B4
P2860
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Effects of antibody, drug and ...... s of antibody-drug conjugates.
@en
type
label
Effects of antibody, drug and ...... s of antibody-drug conjugates.
@en
prefLabel
Effects of antibody, drug and ...... s of antibody-drug conjugates.
@en
P2860
P921
P1476
Effects of antibody, drug and ...... s of antibody-drug conjugates.
@en
P2093
Heather Donaghy
P2860
P304
P356
10.1080/19420862.2016.1156829
P577
2016-04-05T00:00:00Z